P-260 A more physiological approach to support oocyte activation in cases with fertilization failure

Abstract Study question Can we use a physiological compound to trigger oocyte activation in couples undergoing ICSI with history of fertilization failure due sperm activating factor deficiency? Summary answer In pilot sibling study, using recombinant human phospholipase C-zeta (rhPLCζ) yielded comparable compared conventional method ionomycin. What is known already overcomes most forms male gamete defects, however partial or total still occurs regardless adequate semen parameters and optimal maturity. This has been attributed the lack cytosolic identified as PLCζ. To address this, various approaches assisted have proposed, including exposure chemical electrical stimuli. The popular approach remains be Despite its apparent safety, this stimulus unnatural may aggressive on oocytes. Therefore, propose more by utilizing form specific enzyme. design, size, duration past 2 months, poor at their initial cycles were counseled for (AOA) subsequent cycle after confirmation PLCζ deficiency. Oocytes separated into equal cohorts activated either ionomycin co-injection rhPLCζ during ICSI. Fertilization rates between ionomycin-activated rhPLCζ-activated compared, well couples’ cycles. Participants/materials, setting, methods Six suboptimal outcomes consented study (IRB 0712009553) offered AOA Conventional was carried out exposing post-ICSI oocytes 50 mM had confirmed >95% purity. Our rhPLCζ-activation performed co-injecting spermatozoa 0.4pL (5mg/mL glycerol) Main results role chance Couples (n = 6, female age: 36.2 ± 6yrs, 38.0 7yrs) negative infertility workups normal (3.3 3 mL volume, 42.1 35 x106/mL concentration, 30.8 23% motility, 2.0 1% morphology). They underwent 7 unsuccessful 20.0% (12/60) rate 91.7% cleavage rate, those, transferred stage but did not yield clinical pregnancy. A blastocysts obtained all aneuploid. treatment cycles, overall AGT achieved significantly improved 51.6% (32/62) (P<0.001). We then efficiency two equally distributed cohort. Although mathematically insignificant, observed trend that outperforms ionomycin-activation (67.9% vs 50.0%) (57.1% 47.0%). new embryo 87.5% 81.3%. fresh transfer pregnancy yet, cohort one euploid blastocyst while blastocyst. Limitations, reasons caution While yields method, preliminary, confirmatory outcome yet available. Wider implications findings first attempt sperm-specific protein mimic patient treatment. If data larger series, represent way normalize cases deficiency even different sources spermatozoa. Trial registration number N/A